At Viscera, our mission is to enable preventative treatments through predictive diagnostics. We are developing an innovative diagnostic test for H. pylori which will replace current clinical alternatives and act as a gastric cancer screening method.
Target |
£70,000
|
Minimum |
£5,000
|
Invested |
n/a
|
Previous Rounds | £40,000 |
Stage | Pre-Startup/R&D |
Investor Role | Any |
Sign up now to gain full access to pitches and investor profiles
global:publish_msg_immediate
global:publish_msg
You have passed the test and you may continue your with your investment.